Mr. Wilson has served as Chairman of Optimi Health since May 2020. He is a Partner at Very Polite Agency, a global integrated communications and creative firm headquartered in Vancouver, and the founder of Reyal Performance, a men’s performance skincare and supplements brand. His earlier experience includes leading the international expansion of the apparel brand Kit and Ace, where he oversaw retail, brand, and e-commerce growth worldwide.
At Optimi, Mr. Wilson provides strategic oversight and market perspective to the Board. His focus is on positioning the Company as a trusted global manufacturer of psychedelic medicines, with an emphasis on brand, patient accessibility, and long-term growth.
Mr. Stevens has served as Chief Executive Officer of Optimi Health since October 2024, and as a Director and Co-Founder since 2020. With almost two decades of experience in sourcing, manufacturing, and global distribution, he built vertically integrated businesses by managing every stage of the supply chain, gaining a practical understanding of efficiency, quality, and reliable access.
At Optimi, Mr. Stevens applies this experience to pharmaceutical manufacturing with a focus on patients. Under his leadership, the Company is producing GMP-certified MDMA and natural psilocybin and making them available through regulated treatment programs. His goal is to ensure that people living with PTSD, depression, and other mental health conditions can access safe and affordable medicines through pathways that already exist, beginning with Australia’s Authorized Prescriber Scheme.
Mr. Safarik has served as Chief Financial Officer and Director of Optimi Health since 2020. He brings more than 16 years of experience in accounting, project finance, business development, and quality assurance. A Chartered Professional Accountant, he began his career supporting businesses with financial reporting, compliance, and risk management across diverse sectors.
At Optimi, Mr. Safarik is responsible for financial strategy, capital allocation, and disciplined cost management. His approach is centered on building a sustainable foundation that allows the Company to expand patient access responsibly, ensuring long-term impact for both shareholders and the patients who rely on Optimi’s medicines.
Mr. Safarik has served as Chief Operating Officer and Director of Optimi Health since 2020. With nearly two decades of senior management experience across fisheries, agriculture, and regulated industries, he has led operations at scale, including serving as Director of Marine Operations at Ocean Fisheries Ltd. prior to its sale to the Jim Pattison Group. He later co-founded a federally licensed cannabis production company, gaining direct experience in regulatory compliance and controlled manufacturing.
At Optimi, Mr. Safarik oversees production and operations with a focus on efficiency, quality, and scale. His priority is ensuring that the Company’s GMP-certified psychedelics are manufactured to the highest standards and reliably supplied to patients through regulated treatment frameworks.
Mr. Schintler has served as our independent director since October 2020. Mr. Schintler brings 19 years of experience working in the clean energy industry to the Board. He has held leadership and executive positions running and leading over $4 billion in project transactions. Mr. Schintler specializes in project development and capital market financings and has executed on dozens of wind, solar, hydro, natural gas and geothermal generation projects in North America and internationally. He played a lead role in selling Alterra Power Corporation in 2018, a transaction valued at $1.1 billion. He currently serves as capital markets lead at rPlus Energies LLC. Mr. Schintler graduated from the University of Iowa and in 2007 earned the CFA designation.